Lessons for preparedness and reasons for concern from the early COVID-19 epidemic in Iran.

COVID-19 Excess mortality Non-pharmaceutical interventions (NPIs) Phylogenetics SEIR modelling Under-reporting

Journal

Epidemics
ISSN: 1878-0067
Titre abrégé: Epidemics
Pays: Netherlands
ID NLM: 101484711

Informations de publication

Date de publication:
09 2021
Historique:
received: 21 10 2020
revised: 23 05 2021
accepted: 26 05 2021
pubmed: 22 6 2021
medline: 9 9 2021
entrez: 21 6 2021
Statut: ppublish

Résumé

Many countries with an early outbreak of SARS-CoV-2 struggled to gauge the size and start date of the epidemic mainly due to limited testing capacities and a large proportion of undetected asymptomatic and mild infections. Iran was among the first countries with a major outbreak outside China. We constructed a globally representative sample of 802 genomes, including 46 samples from patients inside or with a travel history to Iran. We then performed a phylogenetic analysis to identify clades related to samples from Iran and estimated the start of the epidemic and early doubling times in cases. We leveraged air travel data from 36 exported cases of COVID-19 to estimate the point-prevalence and the basic reproductive number across the country. We also analysed the province-level all-cause mortality data during winter and spring 2020 to estimate under-reporting of COVID-19-related deaths. Finally, we use this information in an SEIR model to reconstruct the early outbreak dynamics and assess the effectiveness of intervention measures in Iran. By identifying the most basal clade that contained genomes from Iran, our phylogenetic analysis showed that the age of the root is placed on 2019-12-21 (95 % HPD: 2019-09-07 - 2020-02-14). This date coincides with our estimated epidemic start date on 2019-12-25 (95 %CI: 2019-12-11 - 2020-02-24) based air travel data from exported cases with an early doubling time of 4.0 (95 %CI: 1.4-6.7) days in cases. Our analysis of all-cause mortality showed 21.9 (95 % CI: 16.7-27.2) thousand excess deaths by the end of summer. Our model forecasted the second epidemic peak and suggested that by 2020-08-31 a total of 15.0 (95 %CI: 4.9-25.0) million individuals recovered from the disease across the country. These findings have profound implications for assessing the stage of the epidemic in Iran despite significant levels of under-reporting. Moreover, the results shed light on the dynamics of SARS-CoV-2 transmissions in Iran and central Asia. They also suggest that in the absence of border screening, there is a high risk of introduction from travellers from areas with active outbreaks. Finally, they show both that well-informed epidemic models are able to forecast episodes of resurgence following a relaxation of interventions, and that NPIs are key to controlling ongoing epidemics.

Identifiants

pubmed: 34153623
pii: S1755-4365(21)00028-1
doi: 10.1016/j.epidem.2021.100472
pmc: PMC8163697
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100472

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M011224/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Mahan Ghafari (M)

Department of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK. Electronic address: mahan.ghafari@zoo.ox.ac.uk.

Bardia Hejazi (B)

Department of Physics, Wesleyan University, Middletown, CT, USA.

Arman Karshenas (A)

Department of Engineering, University of Oxford, Oxford, UK.

Stefan Dascalu (S)

Department of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; Avian Influenza Virus, The Pirbright Institute, Woking, UK.

Alireza Kadvidar (A)

Center for Statistical and Operational Research, Statsminute Company, Tehran, Iran.

Mohammad A Khosravi (MA)

Kawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran.

Maryam Abbasalipour (M)

Kawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran.

Majid Heydari (M)

Editorial Board, Donya-e-Eqtesad Daily Newspaper, Tehran, Iran.

Sirous Zeinali (S)

Kawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran; Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Luca Ferretti (L)

Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.

Alice Ledda (A)

Department of Infectious Disease Epidemiology, Imperial College London, UK.

Aris Katzourakis (A)

Department of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK. Electronic address: aris.katzourakis@zoo.ox.ac.uk.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH